---
figid: PMC5593081__nihms900761f2
figtitle: Inflammasomes and Cancer
organisms:
- NA
pmcid: PMC5593081
filename: nihms900761f2.jpg
figlink: /pmc/articles/PMC5593081/figure/F2/
number: F2
caption: Recognition of pathogen-associated molecular patterns (PAMPs) or danger-associated
  molecular patterns (DAMPs) by inflammasome-initiating sensors leads to the activation
  of the inflammasome and initiation of pyroptosis and release of the bioactive form
  of IL-1β and IL-18 (). IL-1β and IL-18 engage in autocrine and paracrine signaling
  pathways via the IL-1 receptor (IL-1R) and IL-18 receptor (IL-18R), respectively.
  The inflammasome signaling pathway can be inhibited by pharmacological inhibition
  of activation of the inflammasome (Parthenolide, MCC950, Glyburide, and BAY-11–7082)
  (–), ASC oligomerization (CRID3) (), caspase-1 (Thalidomide and Belnacasan or VX-765)
  (,), and IL-1R (Anakinra or Kineret, and Rilonacept or Arcalyst) (,), or neutralizing
  IL-1β (Canakinumab or Ilaris) () or IL-18 (IL-18 binding proteins or IL-18BP) ().
papertitle: Inflammasomes and Cancer.
reftext: Rajendra Karki, et al. Cancer Immunol Res. ;5(2):94-99.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9359196
figid_alias: PMC5593081__F2
figtype: Figure
organisms_ner:
- NA
redirect_from: /figures/PMC5593081__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5593081__nihms900761f2.html
  '@type': Dataset
  description: Recognition of pathogen-associated molecular patterns (PAMPs) or danger-associated
    molecular patterns (DAMPs) by inflammasome-initiating sensors leads to the activation
    of the inflammasome and initiation of pyroptosis and release of the bioactive
    form of IL-1β and IL-18 (). IL-1β and IL-18 engage in autocrine and paracrine
    signaling pathways via the IL-1 receptor (IL-1R) and IL-18 receptor (IL-18R),
    respectively. The inflammasome signaling pathway can be inhibited by pharmacological
    inhibition of activation of the inflammasome (Parthenolide, MCC950, Glyburide,
    and BAY-11–7082) (–), ASC oligomerization (CRID3) (), caspase-1 (Thalidomide and
    Belnacasan or VX-765) (,), and IL-1R (Anakinra or Kineret, and Rilonacept or Arcalyst)
    (,), or neutralizing IL-1β (Canakinumab or Ilaris) () or IL-18 (IL-18 binding
    proteins or IL-18BP) ().
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Parthenolide
  - BAY-11-7082
  - Glyburide
  - Thalidomide
---
